Biocon Biologics and Viatris launch Abevmy, their third oncology biosimilar, in Canada
India’s Biocon Biologics and US-headquartered Viatris (Nasdaq: VTRS) have launched their Abevmy (bBevaczumab) in Canada.
Co-developed by Biocon Biologics and Viatris, Abevmy is a biosimilar to Swiss pharma giant Roche’s (ROG: SIX) Avastin (bevacizumab) and has been approved by Health Canada across four oncology indications.
Abevmy follows the launch of their two oncology biosimilars in Canada, Ogivri (bTrastuzumab) – marketed by Roche as Herceptin -in 2019 – the first trastuzumab approved in the country – and Fulphila (bPegfilgrastim) - Amgen’s (Nasdaq: AMGN) Neulasta copycat, which was launched in 2020. In addition to the therapeutic area of oncology, Viatris Canada launched Hulio (bAdalimumab) – a version of AbbVie’s (NYSE: ABBV) Humira in February 2021 for chronic inflammatory conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze